恒瑞医药(600276.SH)：SHR-3045注射液获得药物临床试验批准

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of SHR-3045 injection, a self-developed biological product aimed at treating rheumatoid arthritis [1] Company Summary - The company’s subsidiary, Guangdong Heng Rui Medicine Co., Ltd. and Shanghai Heng Rui Medicine Co., Ltd. are involved in the clinical trial process for SHR-3045 injection [1] - SHR-3045 injection is expected to suppress immune cell function, reduce inflammation, and improve clinical symptoms in rheumatoid arthritis treatment [1] - The total research and development investment for SHR-3045 injection has reached approximately 35.54 million yuan [1] Industry Summary - Currently, there are no similar drugs approved for market use domestically or internationally, indicating a potential market opportunity for SHR-3045 injection [1]